Why Do Health Systems Not Fund Supervised Exercise Programmes for Intermittent Claudication?
M.A. Popplewell,A.W. Bradbury
DOI: https://doi.org/10.1016/j.ejvs.2014.07.008
IF: 6.427
2014-01-01
European Journal of Vascular and Endovascular Surgery
Abstract:In August 2012 the UK National Institute for Heath and Care Excellence (NICE) published Clinical Guideline (CG) 147 on Peripheral Arterial Disease (PAD).1National Institute for Health and Care Excellence Lower limb peripheral arterial disease: diagnosis and management. (Clinical guideline 147).2012http://www.nice.org.uk/guidance/CG147Google Scholar The recommendations within CG 147 were based on a comprehensive analysis of the available evidence by a multi-disciplinary team of experts from vascular surgery, interventional radiology, vascular nursing, podiatry, primary care, and other stake-holder groups.2Thornton J. Alderson P. Tan T. Turner C. Latchem S. Shaw E. et al.Introducing GRADE across the NICE clinical guideline program.J Clin Epidemiol. 2013; 66: 124-131Abstract Full Text Full Text PDF PubMed Scopus (52) Google Scholar The process was supported by NICE-appointed experts in systematic reviews and statistical/health economic analyses who were working according to well-defined NICE policies and procedures.3National Institute for Health and Care Excellence. Nice clinical guidelines. http://www.nice.org.uk/About/What-we-do/Our-Programmes/NICE-guidance/NICE-guidelines/NICE-clinical-guidelines/ [accessed 10.07.14].Google Scholar CG 147 was supported by the publication of NICE Pathways (Fig. 1) and Quality Standards to assist primary/secondary clinicians and healthcare purchasers (termed commissioners in the UK) to facilitate the implementation of the recommendations across the UK National Health Service (NHS).4National Institute for Health and Care Excellence. Lower limb peripheral arterial disease overview. http://pathways.nice.org.uk/pathways/lower-limb-peripheral-arterial-disease/ [accessed 10.07.14].Google Scholar, 5National Institute for Health and Care Excellence Peripheral arterial disease. (NICE quality standards 52).2014http://www.nice.org.uk/guidance/QS52Google Scholar Regarding the management of intermittent claudication (IC), the commonest clinical manifestation of PAD, NICE CG 147 made strong recommendations regarding the primacy of a supervised exercise programme in the treatment hierarchy (Table 1), while QS 52 recommends that "people with intermittent claudication are offered a supervised exercise programme (SEP)".5National Institute for Health and Care Excellence Peripheral arterial disease. (NICE quality standards 52).2014http://www.nice.org.uk/guidance/QS52Google Scholar NICE is a powerful body within the UK, whose work drives and is driven by national health planning and policy at the highest level; for example, the National Cardiovascular Outcomes Strategy and the NHS Outcomes Framework 2013–2014.6Department of Health Improving cardiovascular disease outcomes: strategy. (Policy paper).2013https://www.gov.uk/government/publications/improving-cardiovascular-disease-outcomes-strategyGoogle Scholar, 7Department of Health NHS outcomes framework 2013 to 2014. (Guidance).2012https://www.gov.uk/government/publications/nhs-outcomes-framework-2013-to-2014Google ScholarTable 1NICE CG 147 recommendations regarding IC.1National Institute for Health and Care Excellence Lower limb peripheral arterial disease: diagnosis and management. (Clinical guideline 147).2012http://www.nice.org.uk/guidance/CG147Google Scholar1.5.1 Offer a supervised exercise programme (SEP) to all people with intermittent claudication (IC).1.5.2 Consider providing a SEP for people with IC which involves: 2 hours of supervised exercise a week for a 3-month period and encourages people to exercise to the point of maximal pain.1.5.3 Offer angioplasty for treating people with SEP only when: advice on the benefits of modifying risk factors has been reinforced (see recommendation 1.2.1) and a SEP has not led to a satisfactory improvement in symptoms and imaging has confirmed that angioplasty is suitable for the person.1.5.4 Do not offer primary stent placement for treating people with IC caused by aorto-iliac disease (except complete occlusion) or femoropopliteal disease.1.5.5 Consider primary stent placement for treating people with IC caused by complete aorto-iliac occlusion (rather than stenosis).1.5.6 Use bare metal stents when stenting is used for treating people with IC.1.5.7 Offer bypass surgery for treating people with severe lifestyle-limiting IC only when: angioplasty has been unsuccessful or is unsuitable and imaging has confirmed that bypass surgery is appropriate for the person.1.5.8 Use an autologous vein whenever possible for people with intermittent claudication having infra-inguinal bypass surgery.1.5.9 Consider naftidrofuryl oxalate for treating people with IC starting with the least costly preparation, only when SEP has not led to satisfactory improvement and the person prefers not to be referred for consideration of angioplasty or bypass surgery. Review progress after 3–6 months and discontinue naftidrofuryl oxalate if there has been no symptomatic benefit. Open table in a new tab Why then has all this work not (as yet) led to a major change in the management of IC across the UK, that is away from early endovascular or surgical revascularisation and towards best medical treatment (BMT) and SEP, with intervention being reserved for a relatively small group of patients who fail to improve or progress despite these evidence-based non-interventional measures? Why is it that NHS (as opposed to research) funded SEPs are still absent from most UK hospitals (NHS Trusts), while at the same time NHS Commissioners appear to be placing no limits on the number of interventions performed for IC? Although this is a complex issue, the reasons seem to fall into three main categories. NICE recognises that further research is needed to explore the effects of SEP on quality of life (QoL) and walking behaviour. The CG 147 research question 4.2 reads "What is the clinical and cost effectiveness of supervised exercise programmes compared with unsupervised exercise for treating people with intermittent claudication, taking into account the effects on long-term outcomes and continuing levels of exercise?". Although a recent Cochrane review showed statistically significant improvements in maximal treadmill walking distance with SEP (as compared with unsupervised programmes), no improvement in QoL was observed.8Fokkenrood H.J. Bendermacher B.L. Lauret G.J. Willigendael E.M. Prins M.H. Teijink J.A. Supervised exercise therapy versus non-supervised exercise therapy for intermittent claudication.Cochrane Database Syst Rev. 2013; 23: CD005263Google Scholar Another small study has shown improvement in QoL when SEP was combined with percutaneous angioplasty.9Bø E. Hisdal J. Cvancarova M. Stranden E. Jørgensen J.J. Sandbæk G. et al.Twelve-months follow-up of supervised exercise after percutaneous transluminal angioplasty for intermittent claudication: a randomised clinical trial.Int J Environ Res Pub Health. 2013; 10: 5998-6014Crossref PubMed Scopus (15) Google Scholar So, doubts about the benefits of SEP over unsupervised exercise, as well as uncertainty regarding the optimum form of SEP, may well be inhibiting NHS Commissioners from investing in non-interventional treatments for IC. Other concerns may include: (i) most randomised trials are small and often under-powered, at least when it comes to sub-group analyses. This has led to calls for more "rigorous and fully powered trials" in exercise therapies.10Galea M.N. Weinman J.A. White C. Bearne L.M. Do behaviour-change techniques contribute to the effectiveness of exercise therapy in patients with intermittent claudication? A systematic review. [Review].Eur J Vasc Endovasc Surg. 2013; 46: 132-141Abstract Full Text Full Text PDF PubMed Scopus (27) Google Scholar (ii) SEP has not been standardised (either in nature or duration), thereby making comparisons difficult.11Delaney C.L. Miller M.D. Chataway T.K. Spark J.I. A randomised controlled trial of supervised exercise regimens and their impact on walking performance, skeletal muscle mass and calpain activity in patients with intermittent claudication.Eur J Vasc Endovasc. 2014; 47: 304-310Abstract Full Text Full Text PDF PubMed Scopus (37) Google Scholar, 12Fakhry F. van de Luijtgaarden K.M. Bax L. den Hoed P.T. Hunink M.G. Rouwet E.V. et al.Supervised walking therapy in patients with intermittent claudication [review].J Vasc Surg. 2012; 56: 1132-1142Abstract Full Text Full Text PDF PubMed Scopus (112) Google Scholar A recent review article has also highlighted the variability in delivery observed in many randomised trials.13Lefebvre K. Cody C. Longaker E. Mason J. Monaghan R. A review of exercise protocols for patients with peripheral arterial disease.Top Geriatr Rehabil. 2013; 29: 165-178Crossref Scopus (2) Google Scholar (iii) A variety of different outcomes measures have been used (treadmill, various walking tests, patient reported outcomes measures based on QoL, health economic metrics such as cost per QALY) and these have resulted in different conclusions being drawn.14Mockford K.A. Gohill R.A. Mazari F. Khan J.A. Vanicek N. Coughlin P.A. et al.Effect of supervised exercise on physical function and balance in patients with intermittent claudication.Br J Surg. 2014; 101: 356-362Crossref PubMed Scopus (11) Google Scholar, 15Mazari F.A. Khan J.A. Carradice D. Samuel N. Gohill R. McCollum P.T. et al.Economic analysis of a randomized trial of percutaneous angioplasty, supervised exercise, or combined treatment for intermittent claudication due to femoropopliteal arterial disease.Br J Surg. 2013; 100: 1172-1179Crossref PubMed Scopus (36) Google Scholar, 16Bermingham S.L. Sparrow K. Mullis R. Fox M. Shearman C. Bradbury A. The cost-effectiveness of supervised exercise for the treatment of intermittent claudication.Eur J Vasc Endovasc Surg. 2013; 46: 707-714Abstract Full Text Full Text PDF PubMed Scopus (36) Google Scholar, 17Al-Jhundi W. Madbak K. Beard J.D. Nawaz S. Tew G.A. Systematic review of home-based exercise programmes for individuals with intermittent claudication.Eur J Vasc Endovasc Surg. 2013; 46: 690-706Abstract Full Text Full Text PDF PubMed Scopus (59) Google Scholar, 18Castro-Sanchez A.M. Mataran-Penarrocha G.A. Feriche-Fernandez-Castanys B. Fernandez-Sola C. Sanchez-Labraca N. Moreno-Lorenzo C. A program of 3 physical therapy modalities improves peripheral arterial disease in diabetes type 2 patients: a randomized controlled trial.J Cardiovasc Nurs. 2013; 28: 74-82Crossref PubMed Scopus (12) Google Scholar (iv) Will the patients turn up and continue to do so? The potential loss of clinical and cost-effectiveness associated with non-attendance is unpopular with purchasers. (v) What happens when the patients stop exercising (under supervision)? Are the observed improvements maintained or will the patients quickly revert to baseline levels of activity?19Fakhry F. Rouwet E.V. den Hoed P.T. Hunink M.G. Spronk S. Long-term clinical effectiveness of supervised exercise therapy versus endovascular revascularization for intermittent claudication from a randomized clinical trial.Br J Surg. 2013; 100: 1164-1171Crossref PubMed Scopus (64) Google Scholar, 20Gardner A.W. Montgomery P.S. Parker D.E. Optimal exercise program length for patients with claudication.J Vasc Surg. 2012; 55: 1346-1354Abstract Full Text Full Text PDF PubMed Scopus (75) Google Scholar Only limited evidence is available attesting to the long-term benefits of SEP.21Guidon M. McGee H. One-year effect of a supervised exercise programme on functional capacity and quality of life in peripheral arterial disease.Disabil Rehabil. 2013; 35: 397-404Crossref PubMed Scopus (43) Google Scholar (vi) How many patients are actually suitable for SEP? Many PAD patients have other comorbidities such as chronic obstructive airways disease and coronary disease that may make them unsuitable and may increase the risks.22Dos Anjos Souza Barbosa J.P. Henriques P.M. de Barros M.V.G. Wolosker N. Ritti-Dias R.M. Physical activity level in individuals with peripheral arterial disease: a systematic review.J Vasc Bras. 2012; 11: 1-7Google Scholar It could also be reasonably argued that the lifestyle choices, behaviours, and personality traits that lead people to develop disabling IC help define a group of people who could not be less likely to comply with, and benefit from, BMT and SEP. It is well documented that patients with PAD have reduced levels of physical activity.23Gardner A.W. Parker D.E. Montgomery P.S. Blevins S.M. Diabetic women are poor responders to exercise rehabilitation in the treatment of intermittent claudication.J Vasc Surg. 2014; 59: 1036-1043Abstract Full Text Full Text PDF PubMed Scopus (53) Google Scholar Clinical experience suggests that a significant number of patients affected by IC are looking for a "quick fix", such as a tablet or an intervention, which places as little burden on them as possible in terms of both taking responsibility for their health as well as the physical effort of complying with treatment. Being brought to and from hospital by an ambulance for a day case angioplasty under local anaesthetic may seem much more preferable to weeks of travelling to a SEP clinic where they will be repeatedly criticised for failing to quit smoking and lose weight!24Hobbs S.D. Bradbury A.W. The Exercise versus Angioplasty in Claudication Trial (EXACT): reasons for recruitment failure and the implications for research into and treatment of intermittent claudication.J Vasc Surg. 2006; 44: 432-433Abstract Full Text Full Text PDF PubMed Scopus (25) Google Scholar The corollary of that is that when, almost inevitably in the face of continued non-compliance with BMT, the angioplasty or bypass fails, the "blame" can be placed firmly on the clinician and not the patient. Last, but by no means least, asking vascular surgeons (VS) and interventional radiologists (IR) to embrace the NICE CG 147 guidelines on IC may be akin to asking "Turkeys to vote for Christmas". Although within the UK NHS (where the overwhelming proportion of interventions for IC are performed) VS and IR are salaried (and are not therefore working in a competitive, fee-for-service, environment), a steady and significant reduction in lower limb interventions as a result of CG 147 would have profound effects upon workload, livelihood, work force planning, and training. VS and IR have made career choices because they like, and professionally validate themselves by, exercising the skills they have acquired to perform interventions. Often the more complex and 'avant garde' the intervention, the better the clinician's kudos within the hospital and at conferences, as well as in terms of income. One cannot also discount the powerful influence of a medical devices industry that makes huge sums of money across the world (often in countries that can ill afford it) out of PAD interventions that often have little or no credible, unbiased evidence of clinical and cost-effectiveness. No wonder then that the manufacturers of balloons, stents and stent-grafts are happy to expend very significant time and resources identifying susceptible "key opinion leaders" who will promote their use for IC and brief against the already unpopular non-interventional therapies. In conclusion, despite clear evidence that significant clinical benefit can be achieved within accepted "willingness to pay" thresholds, and the publication of UK national guidelines, purchasers, patients, and clinicians seem reluctant to accept BMT and SEP as a first line therapy for the overwhelming majority of patients affected by IC. Although further RCTs would be helpful (and are certainly required), the authors would suggest that the main blockage to adopting SEP is not a lack of evidence (many other areas of vascular practice are enthusiastically embraced despite a much lower level of scientific justification), but overcoming patient resistance and professional self-interest. Re-imbursement drives practice and until hospitals are rewarded for running a successful SEP, and at the same time appropriately dis-incentivised from offering intervention until BMT and SEP have been tried and given a chance to work, it seems unlikely that there will be the paradigm shift in the management of IC that the NICE CG 147 has called for.